New Age Alpha Advisors LLC Makes New Investment in Charles River Laboratories International, Inc. (NYSE:CRL)

New Age Alpha Advisors LLC bought a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm bought 18,577 shares of the medical research company’s stock, valued at approximately $3,429,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in Charles River Laboratories International by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company’s stock valued at $1,136,938,000 after acquiring an additional 60,497 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of Charles River Laboratories International by 135,927.9% in the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after purchasing an additional 3,738,018 shares during the last quarter. State Street Corp raised its holdings in shares of Charles River Laboratories International by 2.0% during the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock worth $419,601,000 after buying an additional 41,421 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of Charles River Laboratories International by 2.7% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company’s stock worth $330,231,000 after buying an additional 47,221 shares during the last quarter. Finally, Sei Investments Co. lifted its position in shares of Charles River Laboratories International by 6.1% during the 4th quarter. Sei Investments Co. now owns 673,868 shares of the medical research company’s stock worth $124,394,000 after buying an additional 38,827 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on CRL shares. UBS Group reissued a “neutral” rating and set a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Robert W. Baird lowered their price objective on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a research report on Thursday, February 20th. Redburn Atlantic upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 target price on the stock in a research report on Monday, March 3rd. Bank of America lowered their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. Finally, JPMorgan Chase & Co. cut their price objective on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a report on Thursday, February 20th. One research analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $189.77.

Insider Activity

In other news, COO Birgit Girshick bought 1,514 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The stock was bought at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the purchase, the chief operating officer now directly owns 55,058 shares in the company, valued at approximately $9,064,198.54. This represents a 2.83 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO James C. Foster purchased 6,075 shares of the company’s stock in a transaction that occurred on Thursday, February 20th. The shares were purchased at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the purchase, the chief executive officer now owns 183,639 shares in the company, valued at $30,302,271.39. This trade represents a 3.42 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Stock Performance

CRL stock opened at $155.60 on Friday. The firm has a market cap of $7.96 billion, a PE ratio of 1,037.35, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The stock has a 50-day moving average price of $164.69 and a 200-day moving average price of $182.73. Charles River Laboratories International, Inc. has a 1-year low of $150.79 and a 1-year high of $273.32.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. During the same period in the previous year, the company posted $2.46 earnings per share. The firm’s revenue for the quarter was down 1.1% on a year-over-year basis. As a group, equities research analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).